Please login to the form below
vaccines
This page shows the latest vaccines news and features for those working in and with pharma, biotech and healthcare.
Pfizer’s Prevnar-13 successor takes aim at Merck rival
Pfizer’ s Prevnar-13 successor takes aim at Merck rival. Pfizer just got a leg-up in its race with Merck &Co/MSD to bring a new-generation pneumococcal vaccine to ... continue to build on our expertise in pneumococcal conjugate vaccines with this
Latest news
-
Boehringer’s Corsico to be new GSK drug dev leader
The company achieved three major approvals last year - shingles vaccine Shingrix, respiratory treatment Trelegy Ellipta and HIV combination Juluca.
-
Boehringer bolts on another immuno-oncology company
The company currently has clinical-phase projects ranging across checkpoint inhibitors, oncolytic viruses, cancer vaccines and T-cell engagers, with around half of its early-to-mid-stage pipeline emerging from
-
Pfizer signs $425m flu vaccine deal with Germany’s BioNTech
Pfizer signs $425m flu vaccine deal with Germany’ s BioNTech. Pharma giant will take on development and commercial responsibility for candidates. ... efficient at recruiting immunocompetent cells at the injection site or enable more efficient cellular
-
Your health is about more than just your health
emergency care use, lower use of mammography, lower receipt of influenza vaccine, poorer ability to demonstrate taking medications appropriately, poorer ability to interpret labels and health messages, and, among seniors, poorer
-
China’s BeiGene raises $903m from Hong Kong IPO
The company had been hoping to breach the $1bn threshold with its IPO, but may have been affected by an ongoing scare about the safety of paediatric vaccines in China, which
More from news
Approximately 108 fully matching, plus 1,036 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
cell-based therapies and oncolytic viruses that attack malignant cells directly, and cancer vaccines that try to kickstart an intrinsic immune reaction to the tumour. ... Vaccines. While the first therapeutic cancer vaccines have reached the market, eg
-
Advancing women in healthcare
She joined Merck &Co in 2009 and sees her role in promoting vaccines and facilitating greater access to them in all parts of the world as an extension of this same ... Dr Priya Agrawal is Business Unit Director, Vaccines &Women’s Health at MSD.
-
Uncertainty, austerity and Brexit
Newer plans to lower the QALY for vaccines to £15, 000 should alarm all companies, as it suggests that the QALY for all medicines could also be lowered. ... This is essential. Vaccines are an interesting case study for the post-Brexit world.
-
Health on instalment
The only apt parallel might be the discovery of antibiotics or vaccines, but even those milestones may end up paling in comparison.
-
Deal Watch January 2018
Royalty monetisation, share purchase. 250. Agenus/HealthCare Royalty Partners. Royalties on sales of GSK's QS-21 containing vaccines. ... In October 2017 GSK's QS-21 Stimulon herpes zoster vaccine, Shingrix, was approved by the FDA.
More from intelligence
Approximately 5 fully matching, plus 75 partially matching documents found.
Latest appointments
-
Bone Therapeutics strengthens board with new chairman
He has also been a member of the corporate executive team for GlaxoSmithKline and chief executive officer of GSK Biologicals (now GSK Vaccines).
-
McCann Health appoints Daniel Carucci as global medical director
Dr Carucci has over 25 years of experience in large-scale innovation programs, vaccine development, organisational leadership, and global public health, during which time he served as VP for global health
-
Professor Carole Longson moves from NICE to the ABPI
and the role our members play in developing new innovative medicines and vaccines.
-
Lilly bolsters its oncology team
Furthermore, she has been on the forefront of research in oncology vaccines, immuno-oncology and biosimilars, giving her the unique expertise that will be pivotal in helping us continue to develop
-
Relay Therapeutics appoints Sarah O’Brien as VP of HR
Prior to Sobi, O’Brien spent seven years working at Novartis for its vaccines arm and then with the Novartis Institute for Biomedical Research (NIBR), where she worked closely with the
More from appointments
Approximately 5 fully matching, plus 61 partially matching documents found.
Latest from PMHub
-
Money, sex and power
Social history will record that whilst vaccines, nylon, biotech, the jet engine, the silicon chip, networks, social media and nuclear energy all seemed like big ideas we’ ve only just made
-
PRMA Consulting Ltd
Our experience encompasses a wide range of indications, including; cardiovascular and renal, gastroenterology, immunology, infectious diseases and vaccines, metabolism and endocrinology, neurology and psychiatry, oncology/hematology, ophthalmology,
-
Infographic: The vaccine opportunity in Asia
Infographic: The vaccine opportunity in Asia. As predicted, the vaccine market in emerging and developing countries has continued to expand. ... Download our latest infographic in which we explore the vaccine opportunity in Asia.
-
Case Study: Private market opportunity for a travel vaccine
Case Study: Private market opportunity for a travel vaccine. Our client needed exploratory research to determine the global opportunity for a new travel vaccine in the private market. ... travel. Who the key stakeholders were in each market, in terms of
-
Exploring the Opportunity For Halal In Healthcare
As pork is forbidden by Islam, the use of pork-based gelatin in many vaccines has resulted in considerable resistance to vaccination among the Islamic community. ... Data has demonstrated a decrease in immunization rates in majority Muslim countries such
More from PMHub
Approximately 5 fully matching, plus 27 partially matching documents found.
Featured jobs
-
Systematic Review Lead- London
-
Negotiable
-
Associate Scientific Director
-
Salary TBC
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
- Senior Medical Writer, Principal Medical Writer, Scientific Dire...
-
£40000 - £75000 Bonus Benefits
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Account Director or Senior Account Director
-
Salary TBC
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
Subscribe to our email news alerts
- New Awards scheme for medical and scientific professionals
- Random42 Exhibiting at BioCap Conference 2018
- Bedrock scoops top prizes at Digital Awards
- After Lucentis setback, Novartis trumpets data on follow-up drug
- Labour party divided on Brexit ‘People’s Vote’
- CHMP backs Spark’s Luxturna, but rejects Sarepta again
PMHub
Kendle Healthcare
Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...
Latest intelligence
- The gene therapy revolution
- Gene therapies are bringing new hope for many people with diseases caused by genetic disorders...
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
Quick links
Infographics
